Clinical Trials on Advanced Malignant Solid Tumors in New Zealand

Total 1683 results

Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Recruiting

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

HIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Lymphoma | Multicentric Castleman Disease | Plasmablastic Lymphoma | Kaposi Sarcoma | Recurrent Lymphoma | Anal Carcinoma | Recurrent Kaposi Sarcoma | Recurrent Plasmablastic Lymphoma | Transplant-Related Kaposi Sarcoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Leukemia | Solid Tumor | Hematopoietic Cell Transplantation Recipient

United States, Puerto Rico
Simcha IL-18, Inc.
Merck Sharp & Dohme LLC

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Melanoma | Carcinoma | Renal Cell Carcinoma | Cancer | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple-negative Breast Cancer | MSI-High

United States
Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

Korea, Republic of, United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
Celldex Therapeutics

Recruiting

A Study of CDX-585 in Patients With Advanced Malignancies

Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Hepatic Cancer | Bladder Urothelial Carcinoma | Other Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Non-small Cell Lung Cancer | Solid Tumors | Castration Resistant Prostate Cancer | Microsatellite Stable Colorectal Cancer

Canada, United States, Australia, Israel, Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
PureTech

Recruiting

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Urothelial Carcinoma

United States
Famewave Ltd.
Bristol-Myers Squibb

Active, not recruiting

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Melanoma | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Adenocarcinoma | Papillary Thyroid Cancer

Spain, United States, Israel
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
DEKA Biosciences

Recruiting

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Kidney Cancer | Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Skin Cancer | Pancreas Cancer

United States
Incyte Corporation

Completed

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Breast Cancer | Multiple Myeloma | Gastric Cancer | Lung Cancer | Solid Tumor | Cholangiocarcinoma | Endometrial Cancer | Urothelial Cancer | Myeloproliferative Neoplasms | UC | MPN

United States, Denmark
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Prelude Therapeutics

Completed

A Study of PRT2527 in Participants With Advanced Solid Tumors

Sarcoma | Non-small Cell Lung Cancer | Castrate Resistant Prostate Cancer | Solid Tumors With Known MYC Amplification | Hormone Receptor Positive HER2 Negative Breast Cancer

United States
Recursion Pharmaceuticals Inc.

Recruiting

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Solid Tumor | APC Gene Mutation | AXIN1 Gene Mutation

United States
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy in Treating Patients With Solid Tumors

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Fusion Pharmaceuticals Inc.

Recruiting

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Gastric Cancer | Colorectal Cancer | Ewing Sarcoma | Squamous Cell Carcinoma of Head and Neck | Pancreatic Ductal Adenocarcinoma (PDAC) | NTSR1 Expressing Solid Tumours | Neuroendocrine Differentiated (NED) Prostate Cancer

United States, Australia
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Pfizer

Completed

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Malignant Melanoma | Carcinoma, Squamous Cell of Head and Neck

United States, Australia, Japan, France, Italy
National Cancer Institute (NCI)

Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Multiple Sclerosis | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Systemic Scleroderma | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Psoriatic Arthritis | Inflammatory Bowel Disease | Autoimmune Disease | Sjogren...

United States, Canada
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Registry of Older Patients With Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Cognitive/Functional Effects | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Lynch Syndrome | Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Refractory Ependymoma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Refractory Diffuse Intrinsic Pontine Glioma | Recurrent Brain Neoplasm | Refractory Brain Neoplasm | Constitutional...

United States, Canada
IGM Biosciences, Inc.

Recruiting

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Sarcoma | Acute Myeloid Leukemia | Colorectal Cancer | Solid Tumor | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chondrosarcoma | Small Lymphocytic Lymphoma

United States, Korea, Republic of, France, Spain, Australia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
Pfizer

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Breast Neoplasms | Prostate Cancer | Adenocarcinoma of Lung | Solid Tumors | Liposarcoma | CRC

China, United States, United Kingdom, Mexico, Czechia, Japan, Slovakia, Argentina
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
University of Oklahoma

Active, not recruiting

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (SCC-ClinO+Ge)

Melanoma | Renal Cell Carcinoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Gastrointestinal Cancer | Immune Checkpoint Inhibitors | Squamous Cell Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Patients With Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer

United States, Canada, Puerto Rico
Cybrexa Therapeutics

Active, not recruiting

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Sarcoma | Breast Cancer | Small Cell Lung Carcinoma | Gastric Cancer | Colorectal Cancer | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Urothelial Carcinoma | Solid Tumor, Adult | Appendix Cancer | Esophagus Cancer

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer

Fallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Australia, Bosnia and Herzegovina, Bulgaria, Georgia, Korea, Republic of, Serbia
Amgen

Completed

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Lymphoma | Small Cell Lung Cancer | Multiple Myeloma | Ovarian Cancer | Non-small Cell Lung Cancer | Solid Tumors | Renal Cancer

United States
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

United States, Spain, France, Korea, Republic of, Italy
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Sezary Syndrome | Refractory T-Cell Non-Hodgkin Lymphoma | Merkel Cell Carcinoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extramammary Paget Disease | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin... and other conditions

United States

Clinical Trials on Advanced Malignant Solid Tumors in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations